What really causes weight gain? A fascinating review in the New England Journal of Medicine details myths and facts about obesity.

In June 2012, Medtronic held an Investor Conference to describe its upcoming products and expectations for the next five years. One of the biggest news items for...

When it comes to patient advocacy, Kerri Morrone Sparling explains why even the little things can have a big impact.

(S)he said what?!?

The Journal of the American Medical Association (JAMA) published a controversial meta-analysis suggesting that people who are overweight (a body mass index [BMI] of 25-...

Dr. Diana Guthrie, winner of the AADE Living Legend Award, on controlled breathing and supplements for people with diabetes…

By Hannah Deming Lately, the use of basal insulins (such as Lantus and Levemir) in combination with GLP-1 agonists (such as Byetta , Victoza , and Bydureon ) has been...

Gary Scheiner shares how to make your blood glucose data work for you.

Earlier this month, the American Diabetes Association (ADA) and the co-chairs of the Senate Diabetes Caucus, Senator Susan Collins (R-ME) and Jeanne Shaheen (D-NH),...

(S)he said what?!?

On October 18, Reata and Abbott stopped their phase 3, 2,000-patient BEACON trial for the drug bardoxolone methyl, the most promising candidate in development for the...

On November 14, the European Commission approved AstraZeneca and Bristol-Myers Squibb’s Forxiga (dapagliflozin) for type 2 diabetes throughout the European Union...

Visiting your healthcare team? Kerri Sparling highlights the right questions to ask.

In May, Johnson & Johnson submitted its SGLT-2 inhibitor canagliflozin for approval in the US. On average, the FDA takes about ten months to review applications for...

(S)he said what?!? Last updated September 13, 2012.

(S)he said what?!?

The giant Consumer Electronics Show, held each January in Las Vegas, had a variety of devices relevant to diabetes and obesity this year. Media buzz surrounded the...

Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.

As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...

Kelly on a heated day at the FDA and why a new drug class could bring diabetes patients, doctors, and educators closer to personalized therapy.